Virgan 1.5 mg/g eye ointment
Poland
Table of Contents
Package leaflet: Information for the user
Warning! Keep this leaflet! Information on the immediate packaging in a foreign language.
Virgan 1.5 mg/g eye gel
Ganciclovir
Please read this leaflet carefully before using the medicine, as it contains
important information for the patient.
- Keep this leaflet so that you can read it again if necessary.
- If you have any doubts, consult your doctor or pharmacist.
- This medicine has been prescribed for a specific individual. Do not pass it on to others. The medicine may harm someone else, even if their symptoms are the same.
- If the patient experiences any adverse reactions, including any adverse reactions not listed in this leaflet, inform the doctor or pharmacist. See section 4.
Leaflet contents
- What Virgan is and what it is used for
- Important information before using Virgan
- How to use Virgan
- Possible side effects
- How to store Virgan
- Contents of the pack and other information
1. What Virgan is and what it is used for
Virgan is an eye gel containing an antiviral agent called ganciclovir.
It is indicated for the treatment of certain superficial viral eye infections (cornea).
2. Important information before using Virgan
When not to use Virgan
- if the patient is allergic to ganciclovir, acyclovir, or any of the other ingredients of this medicine (listed in section 6).
- during pregnancy and breastfeeding, unless otherwise advised by a doctor.
- in men and women of childbearing age who are not using a contraceptive method. In addition, men being treated with Virgan are advised to use a local contraceptive method (e.g. condom) during treatment and for three months after its completion. Women being treated with Virgan are advised to use contraceptive measures during treatment and for 6 months after its completion.
Warnings and precautions
Before starting treatment with Virgan, discuss this with your doctor.
- Do not swallow.
- Avoid touching the eyes and eyelids with the dropper tip.
- Contact lenses: Avoid contact of the medicine with soft contact lenses (see also Virgan contains benzalkonium chloride).
Children and adolescents
Due to lack of detailed studies, use in children under 18 years of age is not recommended.
Virgan with other medicines
If the patient is using any other eye drops, they should:
first apply the other ophthalmic medicine,
wait 15 minutes,
then apply Virgan as the last one.
Tell your doctor or pharmacist about all medicines you are currently taking or have recently taken, as well as any medicines you plan to use.
Pregnancy, breastfeeding and effects on fertility
This medicine should not be used during pregnancy and breastfeeding, unless otherwise advised by a doctor.
See also section 2: When not to use Virgan.
If the patient is pregnant, suspects she may be pregnant, or is planning to have a child, she should consult a doctor before using this medicine. Only a doctor can modify the treatment.
Driving and operating machinery
After instillation of the medicine, temporary blurred vision may occur. Wait until vision returns to normal before driving or operating machinery.
Virgan contains benzalkonium chloride
This medicine contains 2.625 micrograms of benzalkonium chloride per drop of gel, equivalent to 0.075 mg/g.
Benzalkonium chloride may be absorbed by soft contact lenses and may cause discoloration of contact lenses. Contact lenses should be removed before applying this medicine and may be reinserted 15 minutes after application.
Benzalkonium chloride may also cause eye irritation, particularly in cases of dry eye syndrome or corneal disorders (the transparent layer at the front of the eye). If the patient experiences unusual eye reactions, such as stinging or eye pain, after using this medicine, they should inform their doctor.
3. How to use Virgan 1.5 mg/g eye gel
Dosage
This medicine should always be used exactly as directed by your doctor or pharmacist. If in doubt,
consult your doctor or pharmacist.
The recommended dose is 1 drop, 3 to 5 times per day.
Use in children
The use of this eye gel in children under 18 years of age is not recommended.
Method of administration
This medicine is intended for ocular (eye) administration to the eye(s) requiring treatment.
Wash your hands thoroughly before applying the medicine.
Look upwards, gently pull the lower eyelid downwards and lightly squeeze the tube to instil the medicine into the infected eye.
Close the tube after use.
- Duration of treatment: Treatment usually does not exceed 21 days.
Use of more than the recommended dose of Virgan
Continue treatment as prescribed by your doctor.
If you have used more than the recommended dose, consult your doctor or pharmacist immediately.
Missed dose of Virgan
Do not use a double dose to make up for a missed dose.
If you have any further doubts concerning the use of this medicine, consult your doctor or pharmacist.
4. Possible adverse reactions
Like all medicines, this medicine can cause adverse reactions, although not everyone will experience them.
Eye disorders:
Very common: may occur in more than 1 in 10 people
- transient burning or stinging, eye irritation, blurred vision.
Common: may occur in less than 1 in 10 people
- keratitis (punctate keratitis), conjunctival hyperaemia (conjunctival congestion).
Reporting of adverse reactions
If any adverse reactions occur, including any adverse reactions not listed in the leaflet, inform a doctor or pharmacist. Adverse reactions can be reported directly to the Department of Monitoring of Adverse Drug Reactions of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: + 48 22 49 21 301, fax: + 48 22 49 21 309; website: https://smz.ezdrowie.gov.pl.
Reporting adverse reactions enables better assessment of the benefit-risk balance of the medicine.
5. How to store Virgan
Keep this medicine out of sight and reach of children.
Store below 25°C.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the stated month.
After opening the tube, do not store the medicine for longer than 4 weeks.
Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. Proper disposal helps protect the environment.
6. Package contents and other information
What Virgan contains
- The active substance is ganciclovir. One gram of gel contains 1.5 mg of ganciclovir.
- Other ingredients: carbomer 974P, sorbitol, sodium hydroxide, benzalkonium chloride, water for injections.
What Virgan looks like and contents of the pack
The medicine is available in a tube containing 5 grams of gel.
For more detailed information, contact the marketing authorisation holder or the parallel importer.
Marketing Authorisation Holder in Romania, country of export:
Laboratoires THEA
12, rue Louis Blériot
63017 Clermont-Ferrand Cedex 2
France
Manufacturer:
FARMILA-THEA FARMACEUTICI S.p.A.
Via Enrico Fermi, 50
Settimo Milanese (MI)
Italy
Parallel Importer:
InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw
Poland
Repackaged by:
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Poland
Marketing Authorisation Number in Romania, country of export: 13277/2020/01
Parallel Import Licence Number: 152/23
This medicine is authorised for sale in the European Economic Area countries under the following names:
Czech Republic, France, Germany, Greece, Hungary, Italy, Luxembourg, Poland, Spain………Virgan